Maxim Group Thinks VistaGen Therapeutics’ Stock is Going to Recover

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGNResearch Report), with a price target of $5.00. The company’s shares closed last Tuesday at $0.97, close to its 52-week low of $0.87.

According to, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of -41.3% and a 10.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for VistaGen Therapeutics with a $7.00 average price target, representing a 609.4% upside. In a report issued on June 22, Robert W. Baird also assigned a Buy rating to the stock with a $9.00 price target.

See the top stocks recommended by analysts >>

Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $357.9K and GAAP net loss of $10.54 million. In comparison, last year the company earned revenue of $441.9K and had a GAAP net loss of $6.21 million.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VTGN in relation to earlier this year. Last month, Shawn Singh, the CEO of VTGN bought 100,000 shares for a total of $100,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Read More on VTGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More